Key result
In patients with cancer-associated thrombotic microangiopathy, treatment with plasma exchange and chemotherapy was associated with an 85% 30-day survival rate versus 20% with plasma exchange alone.
Why the study?
Cancer-associated thrombotic microangiopathy is rare with a poor prognosis, and few data exist regarding the efficacy of plasma exchange and eculizumab in these patients.
Does chemotherapy or eculizumab improve survival in patients with cancer-associated thrombotic microangiopathy compared to plasma exchange alone or no treatment?
Cohort (n=59)
Yes
Does chemotherapy or eculizumab improve survival in patients with cancer-associated thrombotic microangiopathy compared to plasma exchange alone or no treatment?
Absolute Event Rate: 85% vs 20%
Urgent initiation of chemotherapy is associated with significantly longer survival in patients with cancer-associated thrombotic microangiopathy compared to plasma exchange alone.
May support adding chemotherapy to plasma exchange in cancer-associated TMA; leaves open confirmation by randomized trials.
BACKGROUND: Cancer-associated thrombotic microangiopathy (TMA) is a rare disease, with a poor prognosis. The classical treatment is urgent chemotherapy. Few data are available on the efficacy of plasma exchange (PE) and eculizumab in these patients. METHODS: Cases of cancer-related TMA treated between January 2008 and December 2019 in 12 French treatment centres were retrospectively analysed, excluding cases associated with chemotherapy and stem cell transplantation. Patients were divided into four groups depending on the treatment received: none, PE therapy alone, chemotherapy, with or without PE therapy, or eculizumab, with or without chemotherapy and PE therapy. RESULTS: The data of 59 patients with cancer-associated TMA were analysed. Twenty of these cases were related to a cancer recurrence. The cancer was metastatic in 90% of cases (53/59). Bone marrow invasion was observed in 20/41 biopsies. Some laboratory results, including disseminated intravascular coagulation high ferritin and C-reactive protein, were suggestive of cancer. None of the 16 patients whose alternative complement pathway was assessed had abnormal levels of protein expression or activity. The median survival time was 27 days. Chemotherapy was significantly associated with improved survival, with a 30-day survival rate of 85% (17/20) among patients who received PE and chemotherapy, versus 20% (3/15) among patients who received PE alone. Patients treated with eculizumab in addition to chemotherapy and PE therapy did not have longer overall survival or higher haematological remission rates than those treated with chemotherapy and PE therapy alone. Renal remission rates were non-significantly higher, and times to remission non-significantly shorter, in the eculizumab group. CONCLUSIONS: Nephrologists and oncologists should make themselves aware of cancer diagnoses in patients with TMA and bone marrow biopsies should be performed systematically in these cases. All 59 patients had poor survival outcomes, but patients treated with urgent initiation of chemotherapy survived significantly longer than those who were not.
No takes yet. Share an insight, caveat, or question.
Decaestecker et al. (2022) conducted a cohort in Cancer-associated thrombotic microangiopathy (n=59). Plasma exchange and chemotherapy vs. Plasma exchange alone was evaluated on 30-day survival rate. In patients with cancer-associated thrombotic microangiopathy, treatment with plasma exchange and chemotherapy was associated with an 85% 30-day survival rate versus 20% with plasma exchange alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: